Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Immunotherapy"" wg kryterium: Temat


Starter badań:

Tytuł:
CAR T-Cell Therapy for Cancer: Latest Updates and Challenges, with a Focus on B-Lymphoid Malignancies and Selected Solid Tumours.
Autorzy:
Tang HKC; Department of Oncology, Nottingham University Hospitals, Nottingham NG5 1PB, UK.
Wang B; University of Cambridge, Trinity Hall, Cambridge CB3 9DP, UK.
Tan HX; Department of Oncology, Nottingham University Hospitals, Nottingham NG5 1PB, UK.
Sarwar MA; Department of Oncology, Nottingham University Hospitals, Nottingham NG5 1PB, UK.
Baraka B; Department of Oncology, Nottingham University Hospitals, Nottingham NG5 1PB, UK.
Shafiq T; Department of Oncology, Nottingham University Hospitals, Nottingham NG5 1PB, UK.
Rao AR; Department of Oncology, Nottingham University Hospitals, Nottingham NG5 1PB, UK.
Pokaż więcej
Źródło:
Cells [Cells] 2023 Jun 08; Vol. 12 (12). Date of Electronic Publication: 2023 Jun 08.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Immunotherapy, Adoptive*/adverse effects
Neuroblastoma*/pathology
Humans ; Receptors, Antigen, T-Cell/metabolism ; T-Lymphocytes ; Immunotherapy ; CD3 Complex/metabolism ; Tumor Microenvironment
Czasopismo naukowe
Tytuł:
Biological Insight and Recent Advancement in the Treatment of Neuroblastoma.
Autorzy:
Rivera Z; Division of Pediatric Surgery, Department of Surgery, Rush University Medical Center, Chicago, IL 60612, USA.
Escutia C; Division of Pediatric Surgery, Department of Surgery, Rush University Medical Center, Chicago, IL 60612, USA.
Madonna MB; Division of Pediatric Surgery, Department of Surgery, Rush University Medical Center, Chicago, IL 60612, USA.
Gupta KH; Division of Pediatric Surgery, Department of Surgery, Rush University Medical Center, Chicago, IL 60612, USA.; Division of Surgical Oncology, Department of Surgery, Rush University Medical Center, Chicago, IL 60612, USA.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 May 09; Vol. 24 (10). Date of Electronic Publication: 2023 May 09.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Immunotherapy, Adoptive*/methods
Neuroblastoma*/genetics
Neuroblastoma*/therapy
Neuroblastoma*/metabolism
Infant, Newborn ; Child ; Humans ; N-Myc Proto-Oncogene Protein/genetics ; Immunotherapy/methods ; Tumor Microenvironment/genetics
Czasopismo naukowe
Tytuł:
Tumor therapeutic response monitored by telemetric temperature sensing, a preclinical study on immunotherapy and chemotherapy.
Autorzy:
Shao Q; Department of Mechanical Engineering, University of Minnesota, Minneapolis, USA. .
Lundgren M; Department of Radiology, University of Minnesota, Minneapolis, USA.
Lynch J; School of Medicine, University of Minnesota, Minneapolis, USA.
Jiang M; Department of Biomedical Engineering, University of Minnesota, Minneapolis, USA.
Mir M; School of Medicine, University of Minnesota, Minneapolis, USA.
Bischof J; Department of Mechanical Engineering, University of Minnesota, Minneapolis, USA.; Department of Biomedical Engineering, University of Minnesota, Minneapolis, USA.
Nelson M; Department of Radiology, University of Minnesota, Minneapolis, USA.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2023 May 12; Vol. 13 (1), pp. 7727. Date of Electronic Publication: 2023 May 12.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Immunotherapy*
Melanoma*/pathology
Animals ; Temperature ; T-Lymphocytes/pathology ; Immunotherapy, Adoptive/methods ; Tumor Microenvironment
Czasopismo naukowe
Tytuł:
Deciphering and advancing CAR T-cell therapy with single-cell sequencing technologies.
Autorzy:
Huang S; The Second School of Clinical Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, China.; State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Wang X; The Second School of Clinical Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Wang Y; The First School of Clinical Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Wang Y; The Second School of Clinical Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Fang C; The Second School of Clinical Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Wang Y; The Second School of Clinical Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, China.; School of Rehabilitation Sciences, Southern Medical University, Guangzhou, China.
Chen S; The Second School of Clinical Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, China.; State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Chen R; The Second School of Clinical Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Lei T; The Second School of Clinical Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Zhang Y; The Second School of Clinical Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Xu X; State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. .
Li Y; Department of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, China. .; Bioland Laboratory (Guangzhou Regenerative Medicine and Health Guangdong Laboratory), Guangzhou, China. .
Pokaż więcej
Źródło:
Molecular cancer [Mol Cancer] 2023 May 06; Vol. 22 (1), pp. 80. Date of Electronic Publication: 2023 May 06.
Typ publikacji:
Journal Article; Review; Research Support, Non-U.S. Gov't
MeSH Terms:
Immunotherapy, Adoptive*/adverse effects
Receptors, Antigen, T-Cell*/genetics
Humans ; Immunotherapy
Czasopismo naukowe
Tytuł:
The "Great Debate" at Immunotherapy Bridge 2022, Naples, November 30th-December 1st, 2022.
Autorzy:
Ascierto PA; Department of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', Naples, Italy. .
Brentjens R; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Khleif SN; The Loop Immuno Oncology Laboratory, Georgetown University Medical School, Washington, DC, USA.
Odunsi K; University of Chicago Medicine Comprehensive Cancer Center, Chicago, IL, USA.
Rezvani K; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ruella M; Center for Cellular Immunotherapies and Division of Hematology-Oncology, University of Pennsylvania, Philadelphia, PA, USA.
Sullivan RJ; Melanoma Program, Massachusetts General Hospital Cancer Center, Boston, MA, USA.
Fox BA; Earle A. Chiles Research Institute, Robert W. Franz Cancer Research Center, Providence Cancer Institute, Portland, OR, USA.
Puzanov I; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Pokaż więcej
Źródło:
Journal of translational medicine [J Transl Med] 2023 Apr 22; Vol. 21 (1), pp. 275. Date of Electronic Publication: 2023 Apr 22.
Typ publikacji:
Journal Article
MeSH Terms:
Immunotherapy*
Neoplasms*/therapy
Humans ; Immunotherapy, Adoptive ; T-Lymphocytes ; Biomarkers, Tumor ; Tumor Microenvironment
Czasopismo naukowe
Tytuł:
Potent Apoptosis Induction by a Novel Trispecific B7-H3xCD16xTIGIT 2+1 Common Light Chain Natural Killer Cell Engager.
Autorzy:
Ulitzka M; Institute for Organic Chemistry and Biochemistry, Technical University of Darmstadt, Peter-Grünberg-Str. 4, 64287 Darmstadt, Germany.
Harwardt J; Institute for Organic Chemistry and Biochemistry, Technical University of Darmstadt, Peter-Grünberg-Str. 4, 64287 Darmstadt, Germany.
Lipinski B; Institute for Organic Chemistry and Biochemistry, Technical University of Darmstadt, Peter-Grünberg-Str. 4, 64287 Darmstadt, Germany.
Tran H; Institute for Organic Chemistry and Biochemistry, Technical University of Darmstadt, Peter-Grünberg-Str. 4, 64287 Darmstadt, Germany.
Hock B; Institute for Organic Chemistry and Biochemistry, Technical University of Darmstadt, Peter-Grünberg-Str. 4, 64287 Darmstadt, Germany.
Kolmar H; Institute for Organic Chemistry and Biochemistry, Technical University of Darmstadt, Peter-Grünberg-Str. 4, 64287 Darmstadt, Germany.; Centre of Synthetic Biology, Technical University of Darmstadt, 64283 Darmstadt, Germany.
Pokaż więcej
Źródło:
Molecules (Basel, Switzerland) [Molecules] 2024 Mar 04; Vol. 29 (5). Date of Electronic Publication: 2024 Mar 04.
Typ publikacji:
Journal Article
MeSH Terms:
Killer Cells, Natural*
Immunotherapy*
Antibodies, Monoclonal ; Receptors, Immunologic ; Apoptosis
Czasopismo naukowe
Tytuł:
A multi-dimensional approach to unravel the intricacies of lactylation related signature for prognostic and therapeutic insight in colorectal cancer.
Autorzy:
Huang H; Department of Oncology, Shanghai Medical College of Fudan University, Shanghai, China.; Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.; Cancer Institute, Fudan University Shanghai Cancer Center, Shanghai, China.; Institute of Pathology, Fudan University, Shanghai, China.
Chen K; Department of Oncology, Shanghai Medical College of Fudan University, Shanghai, China.; Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.; Cancer Institute, Fudan University Shanghai Cancer Center, Shanghai, China.; Institute of Pathology, Fudan University, Shanghai, China.
Zhu Y; Department of Oncology, Shanghai Medical College of Fudan University, Shanghai, China.; Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.; Cancer Institute, Fudan University Shanghai Cancer Center, Shanghai, China.; Institute of Pathology, Fudan University, Shanghai, China.
Hu Z; Department of Oncology, Shanghai Medical College of Fudan University, Shanghai, China.; Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.; Cancer Institute, Fudan University Shanghai Cancer Center, Shanghai, China.; Institute of Pathology, Fudan University, Shanghai, China.
Wang Y; Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.; Department of Oncology, Shanghai Medical College Fudan University, Shanghai, China.
Chen J; Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.; Department of Oncology, Shanghai Medical College Fudan University, Shanghai, China.
Li Y; Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.; Department of Oncology, Shanghai Medical College Fudan University, Shanghai, China.
Li D; Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, China. li_.; Department of Oncology, Shanghai Medical College Fudan University, Shanghai, China. li_.
Wei P; Department of Oncology, Shanghai Medical College of Fudan University, Shanghai, China. .; Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China. .; Cancer Institute, Fudan University Shanghai Cancer Center, Shanghai, China. .; Institute of Pathology, Fudan University, Shanghai, China. .
Pokaż więcej
Źródło:
Journal of translational medicine [J Transl Med] 2024 Feb 28; Vol. 22 (1), pp. 211. Date of Electronic Publication: 2024 Feb 28.
Typ publikacji:
Journal Article
MeSH Terms:
Immunotherapy*
Colorectal Neoplasms*/genetics
Humans ; Prognosis ; Algorithms ; Cell Line ; Tumor Microenvironment
Czasopismo naukowe
Tytuł:
Baseline Severity and Disease Duration Can Predict the Response to Allergen-specific Immunotherapy in Allergic Rhinitis.
Autorzy:
Li Y; Department of Otolaryngology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China. .
Xiao H; Department of Otolaryngology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China. .
Zeng Y; Department of Otolaryngology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China. .
Tang Y; Department of Otolaryngology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China. .
Zhou L; Department of Otolaryngology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China. .
Liu W; Department of Otolaryngology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China. .
Pokaż więcej
Źródło:
Iranian journal of allergy, asthma, and immunology [Iran J Allergy Asthma Immunol] 2024 Feb 11; Vol. 23 (1), pp. 52-58. Date of Electronic Publication: 2024 Feb 11.
Typ publikacji:
Journal Article
MeSH Terms:
Rhinitis, Allergic*/diagnosis
Rhinitis, Allergic*/therapy
Sublingual Immunotherapy*/methods
Child ; Humans ; Allergens ; Desensitization, Immunologic/methods ; Treatment Outcome ; Immunoglobulin E
Czasopismo naukowe
Tytuł:
Galectin-3 and cancer immunotherapy: a glycobiological rationale to overcome tumor immune escape.
Autorzy:
Scafetta G; Pathology Research Laboratory St, Andrea University Hospital, Via Di Grottarossa 1035, 00189, Rome, Italy.
D'Alessandria C; Klinikum Rechts Der Isar, Nuclear Medicine Department, Technical University Munich, Ismaninger Str. 22, 81675, Munich, Germany.
Bartolazzi A; Pathology Research Laboratory St, Andrea University Hospital, Via Di Grottarossa 1035, 00189, Rome, Italy. .; Pathology Research Laboratory Cancer Center Karolinska, Karolinska Hospital, S-17176, Stockholm, Sweden. .
Pokaż więcej
Źródło:
Journal of experimental & clinical cancer research : CR [J Exp Clin Cancer Res] 2024 Feb 06; Vol. 43 (1), pp. 41. Date of Electronic Publication: 2024 Feb 06.
Typ publikacji:
Letter
MeSH Terms:
Galectin 3*/genetics
Immunotherapy*
Neoplasms*/immunology
Neoplasms*/pathology
Humans ; Tumor Escape ; Tumor Microenvironment
Opinia redakcyjna
Tytuł:
Targeting PCSK9 to upregulate MHC-II on the surface of tumor cells in tumor immunotherapy.
Autorzy:
Wang H; Department of Oncology, Affiliated Hospital of Medical School, Nanjing Drum Tower Hospital, Nanjing University, No. 321, Zhongshan Road, 210008, Nanjing, China.
Zhang X; Department of Oncology, Affiliated Hospital of Medical School, Nanjing Drum Tower Hospital, Nanjing University, No. 321, Zhongshan Road, 210008, Nanjing, China.
Zhang Y; Department of Oncology, Affiliated Hospital of Medical School, Nanjing Drum Tower Hospital, Nanjing University, No. 321, Zhongshan Road, 210008, Nanjing, China.
Shi T; Department of Oncology, Affiliated Hospital of Medical School, Nanjing Drum Tower Hospital, Nanjing University, No. 321, Zhongshan Road, 210008, Nanjing, China.
Zhang Y; Department of Oncology, Affiliated Hospital of Medical School, Nanjing Drum Tower Hospital, Nanjing University, No. 321, Zhongshan Road, 210008, Nanjing, China.
Song X; Department of Oncology, Affiliated Hospital of Medical School, Nanjing Drum Tower Hospital, Nanjing University, No. 321, Zhongshan Road, 210008, Nanjing, China.
Liu B; Department of Oncology, Affiliated Hospital of Medical School, Nanjing Drum Tower Hospital, Nanjing University, No. 321, Zhongshan Road, 210008, Nanjing, China.
Wang Y; Department of Oncology, Affiliated Hospital of Medical School, Nanjing Drum Tower Hospital, Nanjing University, No. 321, Zhongshan Road, 210008, Nanjing, China. .
Wei J; Department of Oncology, Affiliated Hospital of Medical School, Nanjing Drum Tower Hospital, Nanjing University, No. 321, Zhongshan Road, 210008, Nanjing, China. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2024 Apr 10; Vol. 24 (1), pp. 445. Date of Electronic Publication: 2024 Apr 10.
Typ publikacji:
Journal Article
MeSH Terms:
Immunotherapy*
Neoplasms*/genetics
Neoplasms*/therapy
Proprotein Convertase 9*/metabolism
Proprotein Convertases*/antagonists & inhibitors
Genes, MHC Class II*
Animals ; Mice ; Histocompatibility Antigens ; Lipoproteins, LDL ; Receptors, LDL/genetics ; Tumor Microenvironment
Czasopismo naukowe
Tytuł:
State-of-the-Art Cancer Immunotherapies.
Autorzy:
Nagase H; Department of Parasitology, Shinshu University School of Medicine 3-1-1, Asahi, Matsumoto 390-8621, Japan.
Kato T; Department of Cellular and Molecular Immunology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu 514-8507, Japan.; Department of Immunology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan.
Yoshimoto T; Department of Immunoregulation, Institute of Medical Science, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo 160-8402, Japan.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2024 Feb 22; Vol. 25 (5). Date of Electronic Publication: 2024 Feb 22.
Typ publikacji:
Editorial
MeSH Terms:
Immunotherapy*
Neoplasms*
Opinia redakcyjna
Tytuł:
ZFP36 disruption is insufficient to enhance the function of mesothelin-targeting human CAR-T cells.
Autorzy:
Mai D; Department of Bioengineering, University of Pennsylvania, Philadelphia, PA, USA. .; Center for Cellular Immunotherapies, Perelman School of Medicine, Philadelphia, PA, USA. .
Boyce T; Department of Bioengineering, University of Pennsylvania, Philadelphia, PA, USA.
Mehta A; Department of Biology, University of Pennsylvania, Philadelphia, PA, USA.; The Wharton School, University of Pennsylvania, Philadelphia, PA, USA.
Reff J; Center for Cellular Immunotherapies, Perelman School of Medicine, Philadelphia, PA, USA.
Scholler J; Center for Cellular Immunotherapies, Perelman School of Medicine, Philadelphia, PA, USA.
Sheppard NC; Center for Cellular Immunotherapies, Perelman School of Medicine, Philadelphia, PA, USA.; Department of Pathology and Lab Medicine, Perelman School of Medicine, Philadelphia, PA, USA.
June CH; Center for Cellular Immunotherapies, Perelman School of Medicine, Philadelphia, PA, USA.; Department of Pathology and Lab Medicine, Perelman School of Medicine, Philadelphia, PA, USA.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2024 Feb 07; Vol. 14 (1), pp. 3113. Date of Electronic Publication: 2024 Feb 07.
Typ publikacji:
Journal Article
MeSH Terms:
Mesothelin*
Immunotherapy, Adoptive*/methods
Humans ; Animals ; Mice ; T-Lymphocytes/metabolism ; Immunity ; Cytokines/metabolism ; Disease Models, Animal ; Xenograft Model Antitumor Assays ; Cell Line, Tumor ; Tristetraprolin/genetics
Czasopismo naukowe
Tytuł:
Tumor mutational burden predictability in head and neck squamous cell carcinoma patients treated with immunotherapy: systematic review and meta-analysis.
Autorzy:
Rodrigo JP; Department of Otolaryngology, Hospital Universitario Central de Asturias and Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Instituto Universitario de Oncología del Principado de Asturias, University of Oviedo, 33011, Oviedo, Spain.; Ciber de Cáncer, CIBERONC, 28029, Madrid, Spain.
Sánchez-Canteli M; Ciber de Cáncer, CIBERONC, 28029, Madrid, Spain. .; Department of Otolaryngology, Hospital Universitario de Cabueñes and Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), 33011, Oviedo, Spain. .
Otero-Rosales M; Department of Otolaryngology, Hospital Universitario Central de Asturias and Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Instituto Universitario de Oncología del Principado de Asturias, University of Oviedo, 33011, Oviedo, Spain.; Ciber de Cáncer, CIBERONC, 28029, Madrid, Spain.
Martínez-Camblor P; Department of Anesthesiology, Dartmouth Hitchcock Medical Center, Geisel School of Medicine at Dartmouth, Lebanon, NH, USA.; Faculty of Health Sciences, Universidad Autonoma de Chile, 7500912, Providencia, Chile.
Hermida-Prado F; Department of Otolaryngology, Hospital Universitario Central de Asturias and Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Instituto Universitario de Oncología del Principado de Asturias, University of Oviedo, 33011, Oviedo, Spain.; Ciber de Cáncer, CIBERONC, 28029, Madrid, Spain.
García-Pedrero JM; Department of Otolaryngology, Hospital Universitario Central de Asturias and Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Instituto Universitario de Oncología del Principado de Asturias, University of Oviedo, 33011, Oviedo, Spain.; Ciber de Cáncer, CIBERONC, 28029, Madrid, Spain.
Pokaż więcej
Źródło:
Journal of translational medicine [J Transl Med] 2024 Feb 04; Vol. 22 (1), pp. 135. Date of Electronic Publication: 2024 Feb 04.
Typ publikacji:
Meta-Analysis; Systematic Review; Journal Article; Review
MeSH Terms:
Immunotherapy*/methods
Head and Neck Neoplasms*/drug therapy
Head and Neck Neoplasms*/genetics
Humans ; Squamous Cell Carcinoma of Head and Neck/drug therapy ; Squamous Cell Carcinoma of Head and Neck/genetics ; Prognosis ; Survival Analysis ; Biomarkers, Tumor/genetics ; Biomarkers, Tumor/analysis ; Mutation/genetics
Czasopismo naukowe
Tytuł:
Correlation of serum vitamin D concentration with humoral-specific IgG2 and IgG4 levels in high responders to immunotherapy with a 300 IR sublingual house dust mite tablet.
Autorzy:
Fernandez JC; Stallergenes Greer, Antony, France.
Luce S; Stallergenes Greer, Antony, France.
Floch VB; Stallergenes Greer, Antony, France.
Canonica WG; Personalized Medicine, Asthma and Allergy, Humanitas Clinical and Research Center IRCCS, Rozzano, Milan, Italy.; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
Batard T; Stallergenes Greer, Antony, France.
Mascarell L; Stallergenes Greer, Antony, France.
Pokaż więcej
Źródło:
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology [Clin Exp Allergy] 2022 Oct; Vol. 52 (10), pp. 1219-1224. Date of Electronic Publication: 2022 Jul 27.
Typ publikacji:
Letter
MeSH Terms:
Pyroglyphidae*
Sublingual Immunotherapy*
Animals ; Antigens, Dermatophagoides ; Dermatophagoides pteronyssinus ; Dust ; Humans ; Immunoglobulin G ; Immunotherapy ; Tablets ; Vitamin D
Opinia redakcyjna
Tytuł:
Emerging Management Approach for the Adverse Events of Immunotherapy of Cancer.
Autorzy:
Rahman MM; Department of Pharmacy, Faculty of Allied Health Sciences, Daffodil International University, Dhaka 1207, Bangladesh.
Behl T; Chitkara College of Pharmacy, Chitkara University, Rajpura 140401, India.
Islam MR; Department of Pharmacy, Faculty of Allied Health Sciences, Daffodil International University, Dhaka 1207, Bangladesh.
Alam MN; Department of Pharmacy, Faculty of Allied Health Sciences, Daffodil International University, Dhaka 1207, Bangladesh.
Islam MM; Department of Pharmacy, Faculty of Allied Health Sciences, Daffodil International University, Dhaka 1207, Bangladesh.
Albarrati A; Rehabilitation Health Sciences, College of Applied Medical Sciences, King Saud University, Riyadh 12372, Saudi Arabia.
Albratty M; Department of Pharmaceutical Chemsitry, College of Pharmacy, Jazan University, Jazan 45142, Saudi Arabia.
Meraya AM; Practice Research Unit, Department of Clinical Pharmacy, College of Pharmacy, Jazan University, Jazan 45124, Saudi Arabia.
Bungau SG; Department of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea, 410028 Oradea, Romania.; Doctoral School of Biomedical Sciences, University of Oradea, 410073 Oradea, Romania.
Pokaż więcej
Źródło:
Molecules (Basel, Switzerland) [Molecules] 2022 Jun 13; Vol. 27 (12). Date of Electronic Publication: 2022 Jun 13.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Drug-Related Side Effects and Adverse Reactions*
Immunotherapy*/adverse effects
Immunotherapy*/methods
Neoplasms*/drug therapy
Cancer Vaccines/adverse effects ; Cancer Vaccines/therapeutic use ; Humans ; Immune Checkpoint Inhibitors/adverse effects ; Immune Checkpoint Inhibitors/therapeutic use ; Immunologic Factors/adverse effects ; Immunologic Factors/therapeutic use ; Immunotherapy, Adoptive/adverse effects
Czasopismo naukowe
Tytuł:
Cancer Nano-Immunotherapy: The Novel and Promising Weapon to Fight Cancer.
Autorzy:
García-Domínguez DJ; Department of Medical Biochemistry and Molecular Biology, and Immunology, School of Medicine, University of Seville, 41009 Seville, Spain.; Institute of Biomedicine of Seville, IBiS, 41013 Seville, Spain.
López-Enríquez S; Department of Medical Biochemistry and Molecular Biology, and Immunology, School of Medicine, University of Seville, 41009 Seville, Spain.
Alba G; Department of Medical Biochemistry and Molecular Biology, and Immunology, School of Medicine, University of Seville, 41009 Seville, Spain.
Garnacho C; Department of Normal and Pathological Cytology and Histology, School of Medicine, University of Seville, 41009 Seville, Spain.
Jiménez-Cortegana C; Department of Medical Biochemistry and Molecular Biology, and Immunology, School of Medicine, University of Seville, 41009 Seville, Spain.
Flores-Campos R; Department of Medical Biochemistry and Molecular Biology, and Immunology, School of Medicine, University of Seville, 41009 Seville, Spain.; Oncology Service, Department of Medicines, School of Medicine, Virgen Macarena University Hospital, University of Seville, 41009 Seville, Spain.
de la Cruz-Merino L; Institute of Biomedicine of Seville, IBiS, 41013 Seville, Spain.; Oncology Service, Department of Medicines, School of Medicine, Virgen Macarena University Hospital, University of Seville, 41009 Seville, Spain.; Department of Medicine, University of Seville, 41009 Seville, Spain.
Hajji N; Department of Medical Biochemistry and Molecular Biology, and Immunology, School of Medicine, University of Seville, 41009 Seville, Spain.; Cancer Division, Faculty of Medicine, Imperial College London, London SW7 2AZ, UK.
Sánchez-Margalet V; Department of Medical Biochemistry and Molecular Biology, and Immunology, School of Medicine, University of Seville, 41009 Seville, Spain.; Institute of Biomedicine of Seville, IBiS, 41013 Seville, Spain.; Clinical Biochemistry Service, Hospital Universitario Virgen Macarena, University of Seville, 41009 Seville, Spain.
Hontecillas-Prieto L; Department of Medical Biochemistry and Molecular Biology, and Immunology, School of Medicine, University of Seville, 41009 Seville, Spain.; Institute of Biomedicine of Seville, IBiS, 41013 Seville, Spain.; Oncology Service, Department of Medicines, School of Medicine, Virgen Macarena University Hospital, University of Seville, 41009 Seville, Spain.; Clinical Biochemistry Service, Hospital Universitario Virgen Macarena, University of Seville, 41009 Seville, Spain.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2024 Jan 18; Vol. 25 (2). Date of Electronic Publication: 2024 Jan 18.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Immunotherapy*
Neoplasms*/therapy
Humans ; Antigen Presentation ; Immune Evasion ; Nanomedicine ; Tumor Microenvironment
Czasopismo naukowe
Tytuł:
Melatonin as an immunomodulator in CD19-targeting CAR-T cell therapy: managing cytokine release syndrome.
Autorzy:
Zheng N; General Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.
Long Y; Department of Cell Biology, School of Basic Medical Sciences, Nanjing Medical University, Nanjing, Jiangsu, China.
Bai Z; Department of Cell Biology, School of Basic Medical Sciences, Nanjing Medical University, Nanjing, Jiangsu, China.
Li J; Department of Cell Biology, School of Basic Medical Sciences, Nanjing Medical University, Nanjing, Jiangsu, China.
Wang H; Department of Cell Biology, School of Basic Medical Sciences, Nanjing Medical University, Nanjing, Jiangsu, China.
Song DD; Central Laboratory, Hebei Collaborative Innovation Center of Tumor Microecological Metabolism Regulation, Hebei Key Laboratory of Cancer Radiotherapy and Chemotherapy, Affiliated Hospital of Hebei University, Baoding, Hebei, China.
Liu HL; Institute of Clinical Medical Sciences, China-Japan Friendship Hospital, Beijing, China. .
Shi JH; Central Laboratory, Hebei Collaborative Innovation Center of Tumor Microecological Metabolism Regulation, Hebei Key Laboratory of Cancer Radiotherapy and Chemotherapy, Affiliated Hospital of Hebei University, Baoding, Hebei, China. .
Zhao S; General Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China. .
Pokaż więcej
Źródło:
Journal of translational medicine [J Transl Med] 2024 Jan 14; Vol. 22 (1), pp. 58. Date of Electronic Publication: 2024 Jan 14.
Typ publikacji:
Journal Article
MeSH Terms:
Cytokine Release Syndrome*/therapy
Immunotherapy, Adoptive*/adverse effects
Melatonin*/pharmacology
Antigens, CD19 ; Cell- and Tissue-Based Therapy ; Immunologic Factors/pharmacology ; Neoplasm Recurrence, Local ; Receptors, Antigen, T-Cell ; Receptors, Chimeric Antigen ; Animals ; Mice
Czasopismo naukowe
Tytuł:
Navigating the Cytokine Seas: Targeting Cytokine Signaling Pathways in Cancer Therapy.
Autorzy:
Stanilov N; Medical Faculty, Trakia University, 6000 Stara Zagora, Bulgaria.
Velikova T; Medical Faculty, Sofia University St. Kliment Ohridski, 1 Kozyak Str., 1407 Sofia, Bulgaria.
Stanilova S; Department of Molecular Biology, Immunology and Medical Genetics, Medical Faculty, Trakia University, 6000 Stara Zagora, Bulgaria.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2024 Jan 13; Vol. 25 (2). Date of Electronic Publication: 2024 Jan 13.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Immunotherapy*
Neoplasms*/therapy
Humans ; Cell Cycle ; Cytokines ; Inflammation ; Signal Transduction
Czasopismo naukowe
Tytuł:
Prognostic and immune infiltration features of disulfidptosis-related subtypes in breast cancer.
Autorzy:
Chen S; Oncology Department III, The Central Hospital of Xiaogan, No.6, Guangchang Road, Xiaogan City, 432000, Hubei Province, China.
Li X; Oncology Department III, The Central Hospital of Xiaogan, No.6, Guangchang Road, Xiaogan City, 432000, Hubei Province, China.
Ao W; Oncology Department III, The Central Hospital of Xiaogan, No.6, Guangchang Road, Xiaogan City, 432000, Hubei Province, China. .
Pokaż więcej
Źródło:
BMC women's health [BMC Womens Health] 2024 Jan 02; Vol. 24 (1), pp. 6. Date of Electronic Publication: 2024 Jan 02.
Typ publikacji:
Journal Article
MeSH Terms:
Breast Neoplasms*/genetics
Breast Neoplasms*/therapy
Immunotherapy*
Immune Checkpoint Inhibitors*
Female ; Humans ; Cluster Analysis ; Prognosis ; Gene Expression
Czasopismo naukowe
Tytuł:
What Inhibits Natural Killers' Performance in Tumour.
Autorzy:
Papak I; International Centre for Cancer Vaccine Science, University of Gdansk, Ul. Kładki 24, 80-822 Gdansk, Poland.
Chruściel E; International Centre for Cancer Vaccine Science, University of Gdansk, Ul. Kładki 24, 80-822 Gdansk, Poland.
Dziubek K; International Centre for Cancer Vaccine Science, University of Gdansk, Ul. Kładki 24, 80-822 Gdansk, Poland.
Kurkowiak M; International Centre for Cancer Vaccine Science, University of Gdansk, Ul. Kładki 24, 80-822 Gdansk, Poland.
Urban-Wójciuk Z; International Centre for Cancer Vaccine Science, University of Gdansk, Ul. Kładki 24, 80-822 Gdansk, Poland.
Marjański T; Department of Thoracic Surgery, Medical University of Gdansk, 80-210 Gdansk, Poland.
Rzyman W; Department of Thoracic Surgery, Medical University of Gdansk, 80-210 Gdansk, Poland.
Marek-Trzonkowska N; International Centre for Cancer Vaccine Science, University of Gdansk, Ul. Kładki 24, 80-822 Gdansk, Poland.; Laboratory of Immunoregulation and Cellular Therapies, Department of Family Medicine, Medical University of Gdansk, 80-210 Gdansk, Poland.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2022 Jun 24; Vol. 23 (13). Date of Electronic Publication: 2022 Jun 24.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Immunotherapy, Adoptive*/methods
Neoplasms*/therapy
Humans ; Immunotherapy ; Killer Cells, Natural ; T-Lymphocytes
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies